January 11, 2001
ROCKVILLE, Md., Jan 10 /PRNewswire/ via NewsEdge Corporation -
Aixlie Pharmaceuticals today announced that they have obtained the rights to develop two technologies designed by researchers at the Ohio State University. The first, an anticancer vaccine, is designed to stimulate a natural antibody response to Her-2, a protein overexpressed in metastatic breast and ovarian cancers, among others. The first Phase I study in cancer patients is ongoing at Ohio State, and has produced encouraging results to date. "We are excited to license this important technology," stated Dr. Gary Pekoe, Aixlie CEO. "Knowing that a Her-2 monoclonal antibody has in the past been effective in treating metastatic disease, we look forward to providing an effective, active immunotherapy to patients that desire an improved quality of life and a chance for increased survival."
The second technology is a peptide that appears to regulate an important step in the body's autoimmune response. Recent pre-clinical research at Ohio State has indicated that this peptide has the ability to stop the autoimmune destruction of the myelin sheath in an accepted animal model for multiple sclerosis. Researchers have shown the peptide is able not only to prevent the onset of myelin destruction, but also to decrease the process once it has started. "The first Phase I study for the product is being planned currently," stated Dr. Gary Pekoe, Aixlie CEO. "We are impressed by the potential of this technology to impact not only autoimmune neurological diseases like multiple sclerosis, but foresee its testing in organ transplant, diabetes, arthritis, and any number of other conditions involving an autoimmune component."
Aixlie Pharmaceuticals has named Arkios BioDevelopment International to manage the clinical development of the Her-2 vaccine. Arkios has a strong oncology background, having recently completed the Phase II development of another cancer vaccine. Arkios will manage all regulatory, clinical, and biostatistical aspects of the Her-2 vaccine clinical development program. Their services will include data management and the ultimate filing of a Biologic License Application with the Food and Drug Administration.
Aixlie Pharmaceuticals, Inc., a biopharmaceutical company, is dedicated to the development of novel therapies designed to treat cancer, autoimmune, and dermatologic conditions. Aixlie is currently seeking partnerships to develop and commercialize this and other technologies.
For more information, contact Gary Pekoe, PhD, CEO, at 703-242-6835, or at email@example.com.
SOURCE Aixlie Pharmaceuticals, Inc.
CONTACT: Gary Pekoe, PhD, CEO, of Aixlie Pharmaceuticals, Inc., 703-242-6835, or at firstname.lastname@example.org
Web site: http://www.arkios.com